Immunization by exposure to live virus (SIVmne/HIV-2287) during antiretroviral drug prophylaxis may reduce risk of subsequent viral challenge.
Lisa M FrenkelLaRene KullerIngrid A BeckChe-Chung TsaiJaimy P JoyThera M MulvaniaShiu-Lok HuDavid C MontefioriDavid M AndersonPublished in: PloS one (2021)
Repeated exposure to SIVmne or HIV-2287, during antiretroviral prophylaxis that blocked infection, induced binding antibodies in the blood and mucosa, but not neutralizing antibodies or specific cellular immune responses. Studies to determine whether antibodies are similarly induced in breastfeeding infants and sexual partners discordant for HIV infection and receiving pre-exposure antiretroviral prophylaxis are warranted, including whether these antibodies appear to confer partial or complete protection from infection.
Keyphrases
- hiv infected
- antiretroviral therapy
- hiv positive
- human immunodeficiency virus
- hiv aids
- hiv infected patients
- men who have sex with men
- hiv testing
- immune response
- high glucose
- hepatitis c virus
- diabetic rats
- south africa
- sars cov
- oxidative stress
- mental health
- emergency department
- dendritic cells
- adverse drug
- transcription factor
- dengue virus